Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard

Arcus/Gilead Readout Expected Next

 
• By Andrew McConaghie
  
Roche_HQ
Roche has a lot riding on its SKYSCRAPER studies - and still hopes they will yield benefits for patients. • Source: Roche
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip